PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Erythropoietin: An overview • Clinical uses of EPO • Abusive uses of EPO • Risks of EPO use PART 06: Global erythropoietin market PART 07: China: Country snapshot • Social and economic conditions • Healthcare reforms • Healthcare infrastructure PART 08: Opportunities for pharmaceutical vendors in China • Major pharmaceutical vendors in China • Opportunities for global and local vendors PART 09: Biopharmaceutical market in China • Biosimilar market in China • Market size and forecast PART 10: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 11: Market segmentation by end-user • Hospitals • Retail pharmacies PART 12: Market segmentation by application • ESRD • Cancer • HIV • Wounds and neural disease PART 13: Drug pricing and reimbursement in China • Market-driven drug pricing strategy • Scrutinization of illegal pricing of drugs PART 14: Pipeline portfolio • NuPIAO • Uni-EPO-Fc • PEG-EPO PART 15: Market drivers • Increase in CKD and dialysis patient population • Growth in prevalence of cancer • Support for local manufacturers PART 16: Impact of drivers PART 17: Market challenges • Complex regulatory framework and approval process • Complex manufacturing process • Development of alternative therapies PART 18: Impact of drivers and challenges PART 19: Market trends • Penetration of rhEPO drugs in grade I and II hospitals • Exploitation of novel therapeutic areas • Initiation of R&D activities by local/domestic vendors PART 20: Vendor landscape • Competitive scenario • Market analysis 2015 • 3S Bio • Shanghai Chemo • Chengdu Di'ao • NCPC Genetech • Kyowa Hakko Kirin • Shandong Kexing • Other prominent vendors PART 21: Appendix • List of abbreviations PART 22: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Historical timeline of EPO development Exhibit 03: Globally approved EPO biosimilars Exhibit 04: China GDP 2010-2014 ($ trillions) Exhibit 05: China: Healthcare expenditure 2009-2013 (% of GDP) Exhibit 06: Healthcare reforms in China Exhibit 07: China pharmaceutical market overview: SWOT analysis Exhibit 08: New drug approval (NDA) review process in China Exhibit 09: New drug approval process in China Exhibit 10: Drug registration classification and requirements in China Exhibit 11: Notable achievements in biopharmaceutical industry in china Exhibit 12: Biopharmaceutical market in China 2015-2020 ($ billions) Exhibit 13: rhEPO market in China in global biopharmaceutical market 2015 Exhibit 14: rhEPO market in China 2015-2020 ($ millions) Exhibit 15: Five forces analysis Exhibit 16: rhEPO market in China by distribution channels 2015 Exhibit 17: Share of domestic rhEPO drugs in hospitals in China 2015 Exhibit 18: Changes in the drug pricing system before and after 2015 reforms Exhibit 19: Pipeline portfolio: rhEPO market in China Exhibit 20: Impact of drivers Exhibit 21: Impact of drivers and challenges Exhibit 22:S Bio: YoY revenue comparison of EPIAO 2014-2015 ($ millions) Exhibit 23:SBio: Key takeaways Exhibit 24: Shanghai Fosun: YoY revenue and growth rate of blood system products 2013-2015 ($ millions) Exhibit 25: Shanghai Chemo: Key takeaways Exhibit 26: Chengdu Di'ao: Key takeaways Exhibit 27: NCPC Genetech Biotechnology: Key takeaways Exhibit 28: Kyowa Hakko Kirin: Key takeaways Exhibit 29: Shandong Kexing: Key takeaways

3S Bio, Shanghai Chemo, Chengdu Di’ao, NCPC Genetech, Kyowa Hakko Kirin, Shandong Kexing, Ahua Pharmaceutical, Biosidus, Dragon Pharma, Huaxin High Biotechnology, Kehua Bio-Engineering, LG Life Sciences, Shenzhen Sai Bao Er Bio-Pharmaceutical, Sihuan, Shenyang Sunshine Pharmaceutical, Uni-Bio Science Group, Wanbang Biochemical Pharmaceuticals.